ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Article
- Regional, Age, and Sex Patterns of Hepatitis C Virus Infection in Russia: Insights from a 42,000-Participant Serosurvey.Viruses · 2025Article
- Development and Validation of a Machine Learning-Based Screening Algorithm to Predict High-Risk Hepatitis C Infection.Open forum infectious diseases · 2025Article
- Maternal Hepatitis C Virus Infection and Adverse Newborn Outcomes in the US.Maternal and child health journal · 2023Article
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- Maternal hepatitis C virus infection and three adverse maternal outcomes in the United States.PloS one · 2023Article
- Country versus pharmaceutical company interests for hepatitis C treatment.Health care management science · 2022Article
- Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake.Exploratory research in clinical and social pharmacy · 2021Article
- Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.American journal of preventive medicine · 2021Article
- Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.JAMA network open · 2021Article
- Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Accelerating the elimination of hepatitis C in Kuwait: An expert opinion.World journal of gastroenterology · 2020Review
- Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs.Canadian liver journal · 2020Article
- Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study.Journal of viral hepatitis · 2019Article
- Opioid epidemic and liver disease.JHEP reports : innovation in hepatology · 2019Review
- Community screening for hepatitis C virus infection in a low-prevalence population.BMC public health · 2019Article
- Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison.American journal of epidemiology · 2019Article
- Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.Epidemics · 2019Article
- Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.Addiction (Abingdon, England) · 2018Article
- Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.The Lancet. Infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe effectiveness of interferon-free direct-acting antivirals (DAA) in treating chronic hepatitis C virus (HCV) is limited by low screening and treatment rates, particularly among people who inject drugs (PWIDs).
methodsTo evaluate the levels of screening and treatment with interferon-free DAAs that are required to control HCV incidence and HCV-associated morbidity and mortality, we developed a transmission model, stratified by age and by injection drug use, and calibrated it to epidemiological data in the United States from 1992 to 2014. We quantified the impact of administration of DAAs at current and at enhanced screening and treatment rates, focusing on outcomes of HCV incidence, prevalence, compensated and decompensated cirrhosis, hepatocellular carcinoma, liver transplants, and mortality from 2015 to 2040.
resultsIncreasing annual treatment of patients 4-fold-from the approximately 100 000 treated historically to 400 000-is predicted to prevent 526 084 (95% confidence interval, 466 615-593 347) cases of cirrhosis and 256 315 (201 589-316 114) HCV-associated deaths. By simultaneously increasing treatment capacity and increasing the number of HCV infections diagnosed, total HCV prevalence could fall to as low as 305 599 (222 955-422 110) infections by 2040. Complete elimination of HCV transmission in the United States through treatment with DAAs would require nearly universal screening of PWIDs, with an annual treatment rate of at least 30%.
conclusionsInterferon-free DAAs are projected to achieve marked reductions in HCV-associated morbidity and mortality. Aggressive expansion in HCV screening and treatment, particularly among PWIDs, would be required to eliminate HCV in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.